Your browser doesn't support javascript.
Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities.
Liu, Weifang; Yang, Chengzhang; Liao, Yuan-Gao; Wan, Feng; Lin, Lijin; Huang, Xuewei; Zhang, Bing-Hong; Yuan, Yufeng; Zhang, Peng; Zhang, Xiao-Jing; She, Zhi-Gang; Wang, Lei; Li, Hongliang.
  • Liu W; Department of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China; School of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
  • Yang C; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
  • Liao YG; Department of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China.
  • Wan F; Department of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China.
  • Lin L; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
  • Huang X; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
  • Zhang BH; Neonatology Department, Renmin Hospital of Wuhan University, Wuhan, China.
  • Yuan Y; Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Zhang P; School of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
  • Zhang XJ; School of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
  • She ZG; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
  • Wang L; Huanggang Institute of Translational Medicine, Huanggang, China; Department of Neurosurgery, Huanggang Central Hospital, Huanggang, China. Electronic address: wanglei@hgyy.org.cn.
  • Li H; Huanggang Institute of Translational Medicine, Huanggang, China; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic ad
J Infect Public Health ; 15(1): 13-20, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1517346
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) pandemic continues to escalate intensively worldwide. Massive studies on general populations with SARS-CoV-2 infection have revealed that pre-existing comorbidities were a major risk factor for the poor prognosis of COVID-19. Notably, 49-75% of COVID-19 patients had no comorbidities, but this cohort would also progress to severe COVID-19 or even death. However, risk factors contributing to disease progression and death in patients without chronic comorbidities are largely unknown; thus, specific clinical interventions for those patients are challenging.

METHODS:

A multicenter, retrospective study based on 4806 COVID-19 patients without chronic comorbidities was performed to identify potential risk factors contributing to COVID-19 progression and death using LASSO and a stepwise logistic regression model.

RESULTS:

Among 4806 patients without pre-existing comorbidities, the proportions with severe progression and mortality were 34.29% and 2.10%, respectively. The median age was 47.00 years [interquartile range, 36.00-56.00], and 2162 (44.99%) were men. Among 51 clinical parameters on admission, age ≥ 47, oxygen saturation < 95%, increased lactate dehydrogenase, neutrophil count, direct bilirubin, creatine phosphokinase, blood urea nitrogen levels, dyspnea, increased blood glucose and prothrombin time levels were associated with COVID-19 mortality in the entire cohort. Of the 3647 patients diagnosed with non-severe COVID-19 on admission, 489(13.41%) progressed to severe disease. The risk factors associated with COVID-19 progression from non-severe to severe illness were increased procalcitonin levels, SpO2 < 95%, age ≥ 47, increased LDH, activated partial thromboplastin time levels, decreased high-density lipoprotein cholesterol levels, dyspnea and increased D-dimer levels.

CONCLUSIONS:

COVID-19 patients without pre-existing chronic comorbidities have specific traits and disease patterns. COVID-19 accompanied by severe bacterial infections, as indicated by increased procalcitonin levels, was highly associated with disease progression from non-severe to severe. Aging, impaired respiratory function, coagulation dysfunction, tissue injury, and lipid metabolism dysregulation were also associated with disease progression. Once factors for multi-organ damage were elevated and glucose increased at admission, these findings indicated a higher risk for mortality. This study provides information that helps to predict COVID-19 prognosis specifically in patients without chronic comorbidities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans / Male / Middle aged Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article Affiliation country: J.jiph.2021.11.012

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans / Male / Middle aged Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article Affiliation country: J.jiph.2021.11.012